Bioanalytical Method Development and Validation of Memantine in Human Plasma by High Performance Liquid Chromatography with Tandem Mass Spectrometry: Application to Bioequivalence Study

A simple, sensitive, and rapid HPLC-MS/MS method was developed and validated for quantitative estimation of memantine in human plasma. Chromatography was performed on Zorbax SB-C18 (4.6 × 75 mm, 3.5 μm) column. Memantine (ME) and internal standard Memantine-d6(MED6) were extracted by using liquid-liquid extraction and analyzed by LC-ESI-MS/MS using multiple-reaction monitoring (MRM) mode. The assay exhibited a linear dynamic range of 50.00–50000.00 pg/ml for ME in human plasma. This method demonstrated an intra- and interday precision within the range of 2.1–3.7 and 1.4–7.8%, respectively. Further intra- and interday accuracy was within the range of 95.6–99.8 and 95.7–99.1% correspondingly. The mean recovery of ME and MED6 was 86.07 ± 6.87 and 80.31 ± 5.70%, respectively. The described method was successfully employed in bioequivalence study of ME in Indian male healthy human volunteers under fasting conditions

Fabrication and in vitro evaluation of subgingival strips of calcium alginate for controlled delivery of ofloxacin and metronidazole

Objetivos: Elaborar y evaluar tiras subgingivales combinadas compuestas por Ofloxacino y metronidazol in vitro con alginato de calcio biodegradable.Métodos: las tiras se prepararon utilizando el método de evaporación del disolvente. Se usó una concentración del 10% de CaCl2 para la gelificación.de las tiras.Resultados: el grosor de las tiras se encuentra dentro de las recomendaciones (>320 μm). In vitro, la liberación de la droga siguió una cinética bifásica que fue suficiente para alcanzar la CMI e inhibir el crecimiento de microorganismos durante 5 días. La “tasa de liberación de la droga” es inversamente proporcional a la concentración de polímero de la formulación. La liberación de la “droga” fue por difusión y en segunda fase por disolución.Discusión: Las preparaciones OM1 y OM2 que contienen un 90 y un 75% de polímero respectivamente, podrían ser empleadas en liberación controlada durante cinco días en infecciones sublinguales. Siendo el alginato cálcico biodegradable una buena elección como polímero retardanteAim: Subgingival strips of combined ofloxacin (OFX) and metronidazole (MET) were fabricated and evaluated in vitro using biodegradable calcium alginate.Methods: Strips of drug:polymer (10:90, 25:75, 50:50 and 75:25) were prepared using solvent casting method. A 10%w/v CaCl2 solution was used for gelation of the strips.Results: The thickness of strips were at par of recommended thickness (<320 μm). In vitro release of drugs followed a biphasic kinetics which was sufficient to maintain the minimum inhibitory concentrations (MIC) to inhibit the growth of the microorganisms for 5 days. The rate of drug release was inversely proportional to polymer concentration in the formulations. The drug release was by diffusion in second phase of dissolution.Conclusions: The formulations OM1 and OM2 which contain 90 and 75%w/w of polymer could be employed for controlled delivery of combined OFX and MET for 5 days in subgingival infections. Calcium alginate, being a biodegradable is a good choice as drug retarding polymer

SULT1A1 enzyme booster to amplify topical minoxidil response in androgenic alopecia: a single-center prospective study

Background: Androgenetic alopecia (AGA) is a common hair loss disorder affecting individuals across all demographics. Minoxidil, the most widely used treatment for AGA, has limited efficacy, benefiting only 30-40% of users. Previous studies have linked minoxidil's effectiveness to the sulfotransferase enzyme (SULT1A1) in hair follicles, suggesting that boosting this enzyme's activity may improve treatment outcomes in non-responders. Methods: This study aimed to evaluate the effect of a SULT1A1 enzyme booster in enhancing minoxidil response among AGA patients with limited prior improvement. The study enrolled 101 AGA patients who were non-responders to 5% topical minoxidil. Participants were treated with a combination of SULT1A1 adjuvant solution and 5% topical minoxidil for 90 days. Treatment response was evaluated using clinical assessment and statistical analysis to determine the impact of gender and age on outcomes. Results: After 90 days of treatment, 65% of the patients exhibited a positive response to the combination therapy. Gender analysis showed a significantly higher positive response in females compared to males (p<0.05). However, age did not significantly influence treatment outcomes. Conclusion: The combination of SULT1A1 enzyme booster and minoxidil demonstrated a promising increase in response among AGA patients who previously showed limited improvement with minoxidil alone. This study contributes to the limited literature on minoxidil booster responses in AGA, offering hope for improved treatment regimens for affected individuals